|
1
|
Goodwin S, Smith AF and Horning EC:
Alkaloids of ochrosia elliptica labill. J Am Chem Soc.
81:1903–1908. 1959. View Article : Google Scholar
|
|
2
|
Rouësse JG, Le Chevalier T, Caille P,
Mondesir JM, Sancho-Garnier H, May-Levin F, Spielmann M, De Jager R
and Amiel JL: Phase II study of elliptinium in advanced breast
cancer. Cancer Treat Rep. 69:707–708. 1985.PubMed/NCBI
|
|
3
|
Stiborová M, Bieler CA, Wiessler M and
Frei E: The anticancer agent ellipticine on activation by
cytochrome P450 forms covalent DNA adducts. Biochem Pharmacol.
62:1675–1684. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Auclair C: Multimodal action of antitumor
agents on DNA: The ellipticine series. Arch Biochem Biophys.
259:1–14. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Martinkova E, Maglott A, Leger DY, Bonnet
D, Stiborova M, Takeda K, Martin S and Dontenwill M: alpha5beta1
integrin antagonists reduce chemotherapy-induced premature
senescence and facilitate apoptosis in human glioblastoma cells.
Int J Cancer. 127:1240–1248. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kuo PL, Hsu YL, Kuo YC, Chang CH and Lin
CC: The anti-proliferative inhibition of ellipticine in human
breast mda-mb-231 cancer cells is through cell cycle arrest and
apoptosis induction. Anticancer Drugs. 16:789–795. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kuo YC, Kuo PL, Hsu YL, Cho CY and Lin CC:
Ellipticine induces apoptosis through p53-dependent pathway in
human hepatocellular carcinoma HepG2 cells. Life Sci. 78:2550–2557.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fang K, Chen SP, Lin CW, Cheng WC and
Huang HT: Ellipticine-induced apoptosis depends on Akt
translocation and signaling in lung epithelial cancer cells. Lung
Cancer. 63:227–234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chavan S, Bray F, Lortet-Tieulent J,
Goodman M and Jemal A: International variations in bladder cancer
incidence and mortality. Eur Urol. 66:59–73. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Amsellem-Ouazana D, Bièche I, Tozlu S,
Botto H, Debre B and Lidereau R: Gene expression profiling of ERBB
receptors and ligands in human transitional cell carcinoma of the
bladder. J Urol. 175:1127–1132. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pliarchopoulou K, Laschos K and Pectasides
D: Current chemotherapeutic options for the treatment of advanced
bladder cancer: A review. Urol Oncol. 31:294–302. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Peng CY, Graves PR, Thoma RS, Wu Z, Shaw
AS and Piwnica-Worms H: Mitotic and G2 checkpoint control:
Regulation of 14–3-3 protein binding by phosphorylation of Cdc25C
on serine-216. Science. 277:1501–1505. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Stiborova M, Poljakova J, Eckschlager T,
Kizek R and Frei E: Analysis of covalent ellipticine- and
doxorubicin-derived adducts in DNA of neuroblastoma cells by the
32P-postlabeling technique. Biomed Pap Med Fac Univ
Palacky Olomouc Czech Repub. 156:115–121. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ghosh S, Kar A, Chowdhury S and Dasgupta
D: Ellipticine binds to a human telomere sequence: An additional
mode of action as a putative anticancer agent? Biochemistry.
52:4127–4137. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhou BB and Elledge SJ: The DNA damage
response: Putting checkpoints in perspective. Nature. 408:433–439.
2000. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Helt CE, Cliby WA, Keng PC, Bambara RA and
O'Reilly MA: Ataxia telangiectasia mutated (ATM) and ATM and
Rad3-related protein exhibit selective target specificities in
response to different forms of DNA damage. J Biol Chem.
280:1186–1192. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Thanasoula M, Escandell JM, Suwaki N and
Tarsounas M: ATM/ATR checkpoint activation downregulates CDC25C to
prevent mitotic entry with uncapped telomeres. EMBO J.
31:3398–3410. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Graves PR, Lovly CM, Uy GL and
Piwnica-Worms H: Localization of human Cdc25C is regulated both by
nuclear export and 14-3-3 protein binding. Oncogene. 20:1839–1851.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Taylor WR and Stark GR: Regulation of the
G2/M transition by p53. Oncogene. 20:1803–1815. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim JY, Lee SG, Chung JY, Kim YJ, Park JE,
Koh H, Han MS, Park YC, Yoo YH and Kim JM: Ellipticine induces
apoptosis in human endometrial cancer cells: The potential
involvement of reactive oxygen species and mitogen-activated
protein kinases. Toxicology. 289:91–102. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kuo PL, Hsu YL, Chang CH and Lin CC: The
mechanism of ellipticine-induced apoptosis and cell cycle arrest in
human breast MCF-7 cancer cells. Cancer Lett. 223:293–301. 2005.
View Article : Google Scholar : PubMed/NCBI
|
